# An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate

> **NCT01764997** · PHASE3 · TERMINATED · sponsor: **Sanofi** · enrollment: 776 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Sarilumab
- **DRUG:** Etanercept
- **DRUG:** Methotrexate
- **DRUG:** Placebo (for sarilumab)
- **DRUG:** Placebo (for etanercept)
- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT01764997
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-04
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 776 (ACTUAL)
- **Why stopped:** Due to small number of participants entering randomization. Not a safety issue.
- **Last updated:** 2017-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01764997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01764997, "An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01764997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*